Tag: Cancer: Lung
Tagrisso Approved as Adjuvant Therapy for NSCLC With EGFR Mutations
Current approval of the once-daily tablet indicated for patients who have undergone complete tumor removal
Immune Checkpoint Inhibitor Therapy Tied to Cardiac Event Risk
Increased risks persist beyond six months for patients with lung cancer receiving PD1i and with malignant melanoma receiving CTLA-4i
Oral Microbiome Tied to Lung Cancer Risk in Never-Smokers
Risk varies according to profile of the oral microbiota; risk lower with greater abundance of Spirochaetia, Bacteroidetes
Genetic Ancestry Tied to Lung Cancer Mutations in Latin Americans
Mutation frequencies of EGFR and KRAS were 30 and 10 percent, respectively, and 23 and 13 percent, respectively, for Mexican and Colombian patients
Women Have Lower Risk for Death After Resection for Lung Cancer
Restricted mean survival time difference was 0.84 years at 10 years for women undergoing pulmonary resection
ALA: Lung Cancer Survival Has Increased Nationally to 22.6 Percent
People of color face worse outcomes, have lower likelihood of being diagnosed early, receiving surgery
Less Than One in 20 Eligible Adults Receives Lung Cancer Screening
Lung cancer screening at the state level does not correlate with lung cancer burden
Lorlatinib Superior to Crizotinib for ALK-Positive NSCLC
Interim analysis shows risk for disease progression or death lower for first-line therapy with lorlatinib versus crizotinib
Use of Common Meds Tied to Lower Lung Cancer Mortality
